Bharath (@Quest_for_value) header
Bharath (@Quest_for_value) profile picture

Son | Father | Husband | Brother | Supply Chain Consultant | Invests in great businesses going through temporary setbacks

Hyderabad, India
Joined April 2020
Photo by Bharath (@Quest_for_value)Photo by Bharath (@Quest_for_value)Photo by Bharath (@Quest_for_value)Photo by Bharath (@Quest_for_value)Photo by Bharath (@Quest_for_value)Photo by Bharath (@Quest_for_value)Photo by Bharath (@Quest_for_value)Photo by Bharath (@Quest_for_value)Photo by Bharath (@Quest_for_value)Photo by Bharath (@Quest_for_value)
In CDMO Industry, Big can get disproportionately bigger Sharing my revenue projections for Divi's Fundamentally, Divi's appears to be at an inflection point But Valuations are damm expensive How much of future growth is already baked in price? Only time will tell!
"Divi’s is too big to grow fast!" I Heard this argument many times. Many are underestimating the CDMO snowball effect. In this business, big can get disproportionately bigger. The BIG question: FY24 revenue is ₹7,800 Cr. By when does 7800 Cr become yearly PAT??
7
14
2
149
13,038
Divi's guided to be top 3 Globally in Peptides If Wuxi can hit $2.5 Billion with 100 KL SPPS, how much can Divis do with 60KL and Laurus with <XX> KL Note: Until recently, India had virtually ZERO commercial peptide revenue from Innovators This is Day 1, not the endgame!
🇨🇳WuXi is on track to hit $2.5 Billion peptide revenue with 100 KL SPPS capacity With significant peptide capacities coming online, How big can peptides become for players like #Laurus and #Divi’s? 🇮🇳 For context: FY26 entire Indian CDMO sector's revenue is less than $2.5B
10
32
3
259
30,100
Beauty is in the eye of the beholder Trailing P/E says EXPENSIVE. But what does Forward P/E tell us? 🤔 Lets revisit this in April 2028 and see how many CDMO's would be in Top 3 in Nifty Pharma? Time will tell! ⏳
Pharma Rally - Leadership Change coming or Correction in a Few Names. Some Top Pharma names are now at 10X+ Sales and 80-100 PE. What Say?
1
5
1
67
4,285
"Divi’s is too big to grow fast!" I Heard this argument many times. Many are underestimating the CDMO snowball effect. In this business, big can get disproportionately bigger. The BIG question: FY24 revenue is ₹7,800 Cr. By when does 7800 Cr become yearly PAT??
I repeat… FY27 and 28 are going to be great years for Indian CDMO Industry…. Companies with Capacities and Capabilities will benefit significantly from upcoming wave of demand from Global Innovators… Trailer done… Show starts now… 👍
8
5
2
147
40,467
The longer I invest the more I realize you get 1-2 great opportunities every few years Rest of the time is spent wondering if you will ever get another great opportunity again and convincing yourself to own mediocre companies Mediocrity is the price you pay for impatience -Ian
3
15
1
157
9,470
🇨🇳WuXi is on track to hit $2.5 Billion peptide revenue with 100 KL SPPS capacity With significant peptide capacities coming online, How big can peptides become for players like #Laurus and #Divi’s? 🇮🇳 For context: FY26 entire Indian CDMO sector's revenue is less than $2.5B
Peptides are about to rewrite the playbook for Indian CDMOs Don't believe it? Look at WuXi's EBITDA margins: FY20 Ebitda: 24% FY26 Ebitda: 50% That single trendline tells the entire story🚀 Indian CDMO's with ready peptide Capacities and Capabilities to benefit significantly
4
10
2
101
33,433
Real respect is earned when your competitors become your fans. Nothing validates more than Competitor Praising you #Laurus #Divis Source: Cohance Q1FY27 Concall bseindia.com/xml-data/corpfi…
5
10
109
8,209
#LaurusLabs Insane power of Operating Leverage 👀 FY24 PAT: ₹160 Cr ➔ Became Quarterly PAT in 5 Quarters FY25 PAT: ₹360 Cr ➔ Became Quarterly PAT in 5 Quarters again Now FY26 PAT sits at ₹890 Cr How long until ₹890 Cr becomes a single-quarter run rate? Any Guesses?
FY25 EPS > 2 times FY24 EPS FY26 EPS > 2 times FY25 EPS FY27 EPS > 2 times FY26 EPS Satyameva Jayate.... 🫧
10
12
2
133
11,433
The Difference between what you modeled in spreadsheet and the outcome you get is the "Management". - by Ian Cassel Randomness can Surprise even the best analyst.... #Lauruslabs
Ask what has to go right and what it could cost you if you're wrong. I created this using an interesting valuation framework by @unseenvalue , dedicated to all the Laurus bulls.
2
7
73
6,017
Being concentrated investor has allowed me to learn the hard lessons quicker because each decision's outcome is amplified
4
2
68
3,938
“You can always tell the markets are reaching a peak when there are a flurry of people becoming full-time Private investors or traders. They make the decision at the top.” By @iancassel in “Stock Picker” book
3
5
1
74
9,444
When a conservative player like Neuland commits to 200 acres of greenfield capex, it’s not just expansion—it’s a signal. CDMO tailwinds are getting stronger...🚀 The runway may be far longer than what market is pricing in.
A day at #BioAsia2026 and the message is loud & clear.... CDMO is multi-year structural supercycle in the making. Do your homework...
2
13
2
145
11,625
Peptides are about to rewrite the playbook for Indian CDMOs Don't believe it? Look at WuXi's EBITDA margins: FY20 Ebitda: 24% FY26 Ebitda: 50% That single trendline tells the entire story🚀 Indian CDMO's with ready peptide Capacities and Capabilities to benefit significantly
11
30
5
238
98,362
The true character of a person—or an institution—is revealed by how they behave when nobody is watching. SEBI can’t be the watchdog for everything. Accountability ultimately begins with integrity.
Vikas bhai, let me start where you ended: Amrit Kaal. As far as I remember from my teens and 20s, Dr Manmohan Singh’s tenure as finance minister under Shri PV Narasimha Rao could itself be called Amrit Kaal 1.0. I won’t go further back to Pandit Nehru ji, as I wasn’t born then. 😄 Shri Atal Bihari Vajpayee ji’s era, including Pokhran-2 and the structural changes that followed, could easily be Amrit Kaal 2.0. India was a much smaller economy in the 1990s. On a much larger base today, the rate of change has to be meaningfully higher to justify Amrit Kaal 3.0. But that is not the crux of my post. Let us come back to the actual issue. You have skipped the two Taleb lines that were central to my argument: “I have two cats and a mortgage.” and ... “If you see fraud and don’t say fraud, you are a fraud.” My point was never that India has not progressed. Of course it has. Nor was I questioning SEBI’s considerable progress in reducing information asymmetry. My point is about incentives, access and how management behaves when confronted with uncomfortable questions. You correctly say quarterly calls are not mandatory. I never said they were. You guys meet management at will anyway. For you, the earnings call is hardly the only seat at the table. 😆 But DIIs and FIIs meet management teams regularly outside these calls: investor meets, roadshows, conferences, plant visits and one-on-one interactions. That is how the system works. My point is not about mandatory access. It is about fair access to the one forum where everyone is supposedly standing in the same queue. And here in the UK, we have a rather strong cultural preference for respecting the queue. 😄 You know exactly what I mean. I am also not asking SEBI to force companies to conduct five-hour calls. I am asking something much simpler: why not use the available 60 mins fairly? @AnthemBio can do it. @NeulandLabs can do it. Many other companies across market caps can do it. Both keep management commentary concise, spend minimal time reading their presentations aloud, leave adequate time for Q&A and, importantly, treat participants fairly. I have evidence that, on several occasions, @SyngeneIntl has wrapped up its earnings call in around 40 minutes, with a large part of that time spent repeating what was already covered in the press release and presentation. This is not about demanding a 5-hour call. It is about what management chooses to do with the time it has. On Anthem’s 1s earnings call, I was taken in the question queue as an independent investor and was allowed to ask two questions, including one about management’s weaknesses. Management engaged with both. That is the behaviour I am highlighting. Not perfection. Behaviour. And there is an important distinction here. Institutional analysts don't just get a microphone on quarterly calls. They have multiple channels of access to management outside the call. An independent investor sitting in a question queue does not. So the comparison isn't really apples-to-apples. And AGMs are hardly a substitute. In my experience, many digital AGMs reduce shareholder questions to bundled submissions followed by cryptic, carefully sanitised responses, with little scope for follow-up. Too often, the ritual becomes 2 mins praising management, a request for a higher dividend, the voice gets recorded and heard, and then everyone disappears for another year. That is shareholder participation in form, not necessarily in substance. If we are serious about reducing information asymmetry, shareholders need the ability to ask intelligent questions, challenge answers and follow up. A shareholder right that cannot meaningfully challenge management is a procedural right, not meaningful engagement. I have given certain companies repeated opportunities to engage. When the pattern remains unchanged, I put them in the red bucket. Not because they rejected me. Because repeated behaviour becomes data. And I put companies in the green bucket when they demonstrate the opposite behaviour. Take @SyngeneIntl. Please check the actual call durations and transcripts across the quarters. I have evidence of calls ending around the 40-minute mark, with a large chunk of that time spent repeating information already available in the press release and presentation. Do the homework. I suspect the evidence will speak for itself. English may be impeccable. Vocabulary may improve. But shareholders cannot invest in vocabulary. They invest in the quality of the business and the quality of its governance. Finally, I have absolutely no problem with hierarchy in business. A company should absolutely prioritise its most important customers. But shareholders are not customers standing in a sales queue. The question is not whether everyone gets equal time. The question is whether everyone gets a fair opportunity to ask an intelligent question. That is the distinction at the heart of my post. And I deliberately used the Raj analogy as a provocation, not a history lesson. It was a “mirchi trap”. I’ve read Robert Greene too. 😄 Because your response spends considerable time defending India’s progress, SEBI, hierarchy and Amrit Kaal. But it doesn't really address the underlying question: why should access to management depend on institutional pedigree when the question itself is good? That is the conversation I wanted to have. Let us debate that. Not whether India has progressed. We both know it has.
1
2
1
45
23,730
Everyone want 100x stock But Very few can buy through pessimism and disbelief I still remember the skepticism when Laurus was presented at AlphaIdeas session Multibaggers are born in pessimism and validated in hindsight By the time the crowd agrees, the biggest gains are gone
#Lauruslab Nov’22 - @alphaideas event in Mumbai I said “Laurus entered the decade at 3000 cr mcap. Will exit at 3 lac cr mcap” Mcap then was 20k, everyone laughed. Nov’23 - same event- repeated same statement. Mcap then was 15k - everyone mocked Nov’25 - same event- again same statement. Mcap was 50k - everyone got serious Aug’26 - 1 lac cr MCap If Direction is right, destination is certain
1
3
1
106
7,605
In 2022, when Laurus was building capacities, Kotak said it is building "Castle in the Sky." Rest is History.. Stock is up more than 5X in 3 years When something is free, then you are the Product... Read the reports, but do not get influenced by their recommendations... :)
Kotak Saying "Not the time to Buy" exactly when its time to load the truck.... Stock is more than 3X from then in 2 years. When something is free, then you are the Product... Read the reports, but do not get influenced by their recommendations... :) #Lauruslabs
8
9
1
144
14,186
Q1FY27 results have surprised even the bulls… #Lauruslabs
Laurus will eventually kill the bears and will surprise the bulls…. FY25 is the year to watch… CDMO and bio should be around 2500 in FY25…. This itself will be valued at 25K crores… Current market cap 16K crores…. @ValueEducator @jeevanpatwa @unseenvalue
1
3
93
9,677
Laurus labs Single quarter PAT of Q1FY27 > Full-year PAT of FY25 That is the insane power of operating leverage in action
2
18
1
219
11,378
Winter is Over.. Big Daddy is coming out of hibernation mode
5
2
53
13,897
The Show Starts with Q1FY27…. Fasten your Seatbelt’s…
I repeat… FY27 and 28 are going to be great years for Indian CDMO Industry…. Companies with Capacities and Capabilities will benefit significantly from upcoming wave of demand from Global Innovators… Trailer done… Show starts now… 👍
2
5
70
7,184